Northern Trust’s Lantern Pharma LTRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.4K Hold
15,589
﹤0.01% 4332
2025
Q4
$47.2K Hold
15,589
﹤0.01% 4290
2025
Q3
$67.8K Hold
15,589
﹤0.01% 4224
2025
Q2
$49.3K Hold
15,589
﹤0.01% 4237
2025
Q1
$55.2K Buy
15,589
+2,776
+22% +$11.5K ﹤0.01% 4220
2024
Q4
$40.9K Hold
12,813
﹤0.01% 4288
2024
Q3
$47K Hold
12,813
﹤0.01% 4225
2024
Q2
$59.8K Sell
12,813
-10
-0.1% -$60 ﹤0.01% 4179
2024
Q1
$113K Buy
12,823
+230
+2% +$1.23K ﹤0.01% 4047
2023
Q4
$53.9K Hold
12,593
﹤0.01% 4224
2023
Q3
$42.9K Hold
12,593
﹤0.01% 4201
2023
Q2
$71K Sell
12,593
-36
-0.3% -$186 ﹤0.01% 4129
2023
Q1
$61K Hold
12,629
﹤0.01% 4212
2022
Q4
$76.3K Hold
12,629
﹤0.01% 4178
2022
Q3
$60K Hold
12,629
﹤0.01% 4279
2022
Q2
$72K Hold
12,629
﹤0.01% 4292
2022
Q1
$90K Hold
12,629
﹤0.01% 4381
2021
Q4
$101K Hold
12,629
﹤0.01% 4422
2021
Q3
$141K Hold
12,629
﹤0.01% 4311
2021
Q2
$184K Hold
12,629
﹤0.01% 4188
2021
Q1
$229K Buy
+12,629
New +$221K ﹤0.01% 4066

Other funds holding LTRN

Northern Trust's LTRN Position: Q1 2026 in Review

Northern Trust held its Lantern Pharma (LTRN) position steady in Q1 2026 at 15,589 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4332.

Northern Trust first reported a position in LTRN in Q1 2021 and has held it in 21 quarters since. The position peaked at $229K in Q1 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Northern Trust held 15,589 shares of Lantern Pharma worth $21.4K as of Q1 2026.
  • Northern Trust left its Lantern Pharma share count unchanged in Q1 2026.
  • Lantern Pharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4332 holding.
  • Northern Trust first reported a position in Lantern Pharma in Q1 2021 and has held it in 21 quarters since.
  • Northern Trust's Lantern Pharma position peaked at $229K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.